BamSEC and AlphaSense Join Forces
Learn More

Harpoon Therapeutics Inc

Formerly NASDAQ: HARP
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 6 pages Harpoon Therapeutics, Inc. Restricted Stock Unit Award
12/34/56
EX-10.1
from 8-K 3 pages November 26, 2023 Retention Bonus Agreement
12/34/56
EX-10.2
from 8-K 25 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 46 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 27 pages Registration Rights Agreement
12/34/56
EX-10
from 10-K 11 pages January 31, 2023 Holger Wesche, Phd via Electronic Delivery Re: Separation Agreement 1. Termination Date. Your Employment Termination Will Be Effective January 31, 2023 (The “Termination Date”). 2. Severance Benefits. if You Timely Sign This Agreement, Allow the Releases Set Forth Herein to Become Effective, and Remain in Material Compliance With All of Your Legal and Contractual Obligations to the Company, Then the Company Will Provide You With the Following Severance Benefits
12/34/56
EX-10.1
from 8-K 43 pages Securities Purchase Agreement
12/34/56
EX-10
from 10-K 23 pages September 17, 2022 Luke Walker via Email/Docusign Dear Luke, on Behalf of Harpoon Therapeutics, Inc. (“Harpoon” or the “Company”), I Am Pleased to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer: 1)
12/34/56
EX-10.1
from 10-Q 34 pages Harpoon Therapeutics, Inc. 2019 Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 41 pages Harpoon Therapeutics, Inc. 2022 Inducement Plan Adopted by the Board of Directors: June 27, 2022
12/34/56
EX-10.2
from 10-Q 4 pages Harpoon Therapeutics, Inc. Non-Employee Director Compensation Policy Adopted: December 19, 2018 Amended and Restated: March 18, 2021 Amended and Restated: October 25, 2021
12/34/56
EX-10.1
from 10-Q 23 pages October 25, 2021 Julie Eastland via Email/Docusign Dear Julie, on Behalf of Harpoon Therapeutics, Inc. (“Harpoon” or the “Company”), I Am Pleased to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer: 1)
12/34/56
EX-10.23
from 10-K 23 pages October 25, 2021 Julie Eastland via Email/Docusign Dear Julie, on Behalf of Harpoon Therapeutics, Inc. (“Harpoon” or the “Company”), I Am Pleased to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer: 1)
12/34/56
EX-10.22
from 10-K 10 pages October 25, 2021 Gerald McMahon, Phd via Docusign Re: Transition and Retirement Agreement Dear Jerry: This Letter Sets Forth the Substance of the Transition and Retirement Agreement (The “Agreement”) Between You and Harpoon Therapeutics, Inc. (The “Company”). 1
12/34/56
EX-10.1
from 10-Q 10 pages Amendment No. 1 to Amended and Restated Discovery Collaboration and License Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Harpoon Therapeutics, Inc. Non-Employee Director Compensation Policy Adopted: December 19, 2018 Amended and Restated Effective: March 18, 2021
12/34/56
EX-10.2
from 10-Q 2 pages April 15, 2020 Abbvie Biotechnology Ltd. C/O Conyers, Dill & Pearman, Clarendon House, 2 Church Street, Hamilton Hm 11 Bermuda Abbvie Inc. 1 North Waukegan Road North Chicago, Illinois 60064 United States Attention: [***] Dear Sir or Madam: Re: Amendment to Development and Option Agreement Between Harpoon Therapeutics, Inc. (“Harpoon”) and Abbvie Biotechnology Ltd. (“Abbvie”)
12/34/56
EX-10.1
from 10-Q 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.20
from 10-K 8 pages Harpoon Therapeutics, Inc. Fifth Amended and Restated Consulting Agreement
12/34/56
EX-10.19
from 10-K 21 pages Confidential
12/34/56